Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Geale, K
31  Ergebnisse:
Personensuche X
?
1

EE344 Cost per Responder Associated with Bimekizumab Agains..:

Mørup, M. ; Geale, K. ; Ferguson, A...
Value in Health.  26 (2023)  12 - p. S117 , 2023
Link: https://doi.org/10.1016/..
 
?
2

EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-..:

Lyris, N. ; Geale, K. ; Aldvén, M...
Value in Health.  26 (2023)  12 - p. S178 , 2023
Link: https://doi.org/10.1016/..
 
?
3

MSR59 Prediction of Cardiovascular Disease in Psoriasis Pat..:

Lilja, M. ; Geale, K.
Value in Health.  26 (2023)  6 - p. S288 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Care pathways in atopic dermatitis: a retrospective populat..:

von Kobyletzki, L. ; Ballardini, N. ; Henrohn, D....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  9 - p. 1456-1466 , 2022
Link: https://doi.org/10.1111/..
 
?
5

RWD132 Suitability of Nordic Real-World Data to Support EU ..:

Geale, K ; Toresson Grip, E ; Ortsäter, G
Value in Health.  25 (2022)  12 - p. S474-S475 , 2022
Link: https://doi.org/10.1016/..
 
?
6

HPR128 Suitability of Nordic Real-World Data to Support US ..:

Geale, K ; Toresson Grip, E ; Ortsäter, G
Value in Health.  25 (2022)  12 - p. S255 , 2022
Link: https://doi.org/10.1016/..
 
?
7

EPH10 Social Determinants of Health in Swedish Administrati..:

Skröder, H ; Geale, K
Value in Health.  25 (2022)  12 - p. S192 , 2022
Link: https://doi.org/10.1016/..
 
?
8

POSB139 Predicting Quality of Life through Changes in Menst..:

Lilja, M ; Frisell, O ; Borgström, F..
Value in Health.  25 (2022)  1 - p. S88 , 2022
Link: https://doi.org/10.1016/..
 
?
9

PBI25 Longitudinal Trends in the Biologic Treatment of Swed..:

Lilja, M. ; Toresson Grip, E. ; Geale, K.
Value in Health.  23 (2020)  - p. S415 , 2020
Link: https://doi.org/10.1016/..
 
?
10

PIH66 THE ECONOMIC AND PATIENT BURDEN OF MILD-TO-MODERATE A..:

Ortsäter, G. ; Geale, K. ; Rieem Dun, A....
Value in Health.  22 (2019)  - p. S639 , 2019
Link: https://doi.org/10.1016/..
 
?
11

PCN61 A FREELY AVAILABLE GENERIC COST-EFFECTIVENESS MODEL I..:

Lauppe, R. ; Geale, K. ; Lilja, M..
Value in Health.  22 (2019)  - p. S447 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Cost-Effectiveness of Abaloparatide for the Treatment of Po..:

Hansson-Hedblom, A ; Geale, K ; Borgstrom, F...
Value in Health.  21 (2018)  - p. S197 , 2018
Link: https://doi.org/10.1016/..
 
?
13

The Budget Impact of Introducing Demineralised Bone Matrix ..:

Polyzoi, M ; Álvarez, M ; Geale, K...
Value in Health.  20 (2017)  9 - p. A530 , 2017
Link: https://doi.org/10.1016/..
 
?
14

Dose Increase Beyond Labelled Dose of Biologic Treatments I..:

Geale, K ; Costa-Scharplatz, M ; Anell, B...
Value in Health.  20 (2017)  9 - p. A809 , 2017
Link: https://doi.org/10.1016/..
 
?
15

The Association Between Disease Activity and Health-Related..:

Spelman, T ; Geale, K ; Anell, B..
Value in Health.  20 (2017)  9 - p. A728 , 2017
Link: https://doi.org/10.1016/..
 
1-15